Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

Temozolomide, an imidazotetrazine derivative, was given to 18 patients with low-grade non-Hodgkin's lymphoma (NHL) at a dose of 750 mg m-2 orally, divided over five consecutive days, escalated to 1000 mg m-2 over 5 days (i.e. 200 mg m-2 day-1) if no significant myelosuppression was noted at day...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Woll, P. J., Crowther, D., Johnson, P. W., Soukop, M., Harper, P. G., Harris, M., Brampton, M. H., Newlands, E. S.
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 1995
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2034149/
https://ncbi.nlm.nih.gov/pubmed/7599050
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы